Mold-Aversi is commonly used to help with short-term symptomatic assistance for acute diarrhea, which is a condition characterized by periods of heightened symptoms related to excessive intestinal fluid loss. This medication may be part of symptomatic management for these acute episodes when a causal treatment is not feasible.

The treatment is relevant when supportive symptom management is appropriate and is applied in addressing symptoms that create noticeable physiological strain. The treatment is commonly used across conditions presenting with acute episodes, such as acute gastroenteritis and traveler's diarrhea. The use of this treatment may contribute to easing the volume and frequency of stool output by assisting with the moderation of the fluid discharge.

The medication is considered relevant when supportive symptom management is appropriate alongside oral rehydration therapy for both adults and infants and children over three months of age.

“It provides supportive relief that helps patients cope more steadily with the acute episode by managing the distressing manifestations of fluid discharge.”

Quick Fact: Relief for Watery Stools A key patient-oriented benefit is assisting with the moderation of high-volume, watery stools, which contributes to improved comfort and contributes to easing the overall symptom load during the symptomatic phase.

Regulatory References

1. Official Product Information Summary

Eligibility Map: Who Can and Cannot Use Mold-Aversi

Official regulatory documents define the allowed and restricted use of Mold-Aversi (Racecadotril) based on age, physiological status, and underlying health conditions.

Category	Official Regulatory Status/Statement
Populations for whom use is allowed	Adults for symptomatic relief of acute diarrhea. Infants and children 3 months of age and older, when used alongside oral rehydration therapy (ORT).
Populations for whom use is not recommended	Patients with severe renal or hepatic impairment; patients with chronic diarrhea or diarrhea associated with antibiotic treatment; pregnant women; breastfeeding women.
Populations for whom use is contraindicated	Patients with known hypersensitivity to Racecadotril or excipients; infants younger than 3 months of age; patients with a history of angioedema related to enkephalinase inhibitors.

---

Eligibility-Related Restrictions

• Use is contraindicated in individuals with rare hereditary problems such as fructose intolerance or glucose-galactose malabsorption.
• The medicine is not recommended for diarrhea accompanied by fever and bloody/purulent stools, or in cases of severe vomiting.

Regulatory documentation classifies use in groups with insufficient clinical data (e.g., severe organ impairment, pregnancy, lactation) as not recommended, establishing strict limitations that guide who is permitted to use the medicine.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Mold-Aversi (Racecadotril) by establishing a low potential for most common drug–drug interactions, while noting one specific pharmacodynamic risk.

---

Interaction Scope

Interaction Classification	Interacting Substance/Condition	Official Regulatory Statement
Pharmacodynamic Risk	Angiotensin-Converting Enzyme (ACE) Inhibitors	Co-administration is associated with an increased risk of bradykinin-mediated angioedema.
Pharmacokinetic Profile	Major CYP Enzymes (e.g., CYP3A4, 2D6, 2C9)	In vitro data show the substance and its metabolites do not inhibit or induce major CYP enzyme isoforms to a clinically relevant extent.
Transporter/Binding	Highly Protein-Bound Drugs	The substance does not modify the protein binding of other active substances like Warfarin or Digoxin.
Exposure Modification	Loperamide or Nifuroxazide	Concomitant treatment does not modify the kinetics (exposure levels) of the substance in humans.

---

Interaction Constraints

Food Interaction: Co-administration with food officially delays the time to peak plasma concentration (T max) by 60 to 90 minutes but does not alter overall bioavailability (AUC).

Population Notes: Caution is advised regarding potential altered interaction effects in individuals with severe renal or hepatic impairment due to a lack of sufficient clinical experience in these populations, as noted in official prescribing information.

Timing Rules: No mandatory separation windows are specified in the regulatory text for medicinal product co-administration.

Targeting the Enkephalinase Enzyme

Mold-Aversi acts via its active metabolite, Thiorphan, which serves as a highly selective inhibitor of Neutral Endopeptidase (NEP), an enzyme present in the intestinal lining. This inhibition protects the body's natural regulatory peptides, the enkephalins, from rapid degradation, thereby increasing their localized concentration and allowing for prolonged local activity of the enkephalins.

The Antisecretory Signaling Cascade

The potentiated enkephalins enhance the activation of delta-opioid receptors on the intestinal cells, initiating an intracellular cascade that reduces the concentration of the second messenger, cyclic AMP (cAMP). This drop in cAMP is the critical molecular step that leads to the inhibition of the chloride channels that mediate excessive ion and water transport across the epithelial membrane.

Selective Physiological Modulation

The mechanism is selective for the secretion pathway and does not interfere with the natural muscle contractions or transit time of the gut, which are governed by different opioid receptor systems. This peripheral and focused modulation ensures the drug’s action modulates the fluid and ion transport at the cellular level toward a state of reduced epithelial secretion.

How to Use Mold-Aversi: Administration Guidelines

This information details the instructions for the use of Mold-Aversi (Racecadotril).

---

Administration Scope

Property	Description
Route of administration	Oral route for all approved forms (capsules and granules).
Dosing schedule (Adults)	Treatment begins with a single 100 mg capsule dose, followed by a maintenance dose of 100 mg per dose. The total daily intake must not exceed 400 mg.
Dosing schedule (Pediatrics)	Dosage is determined by the child's body weight, typically 1.5 mg/kg per dose, administered as granules.
Timing in relation to meals	Adult capsules are preferably taken before the main meals.
Preparation requirements	Pediatric granules must be mixed into food, dispersed in water, or added to a feeding bottle, followed by immediate administration.
Age-group administration rules	Not for use in infants less than 3 months of age. No dosage adjustment is necessary for older adults.
Special procedural conditions	The medicine must be administered as a complementary treatment alongside Oral Rehydration Therapy (ORT).

---

Procedural Structure and Duration

Classification	Detail
Frequency pattern	Three times daily (t.i.d.) at regular intervals following the initial dose.
Course duration / Cessation	Treatment must continue until two normal stools are recorded, but the total course must not exceed seven days.
Use-context constraints	The regimen is strictly defined as an adjunct to ORT and use in patients with severe hepatic or renal impairment requires caution.

---

The instructions establish a time-bound, short-term protocol for oral intake that requires an initial dose followed by a fixed daily frequency. This procedure is designed to guide administration from initiation to cessation, strictly defining the limits of use by both a maximum duration and a clinical end-point (two normal stools). The regimen is consistently conditional on being applied as a complementary measure to standard fluid replacement protocols.

Research evidence / Overview of studies for Mold-Aversi

Evidence for use in Acute Diarrhea in Children and Infants

The clinical research base for Mold-Aversi primarily involves short-term Randomized Controlled Trials (RCTs) and Systematic Reviews evaluating its use for acute diarrhea in young patients alongside oral rehydration therapy. Studies included infants older than three months through adolescents, covering both hospitalized and at-home settings. Researchers monitored key outcomes related to physical discomfort, including the duration of the diarrheal episode, stool output volume, and the incidence of rehydration failure or need for intravenous fluids. Findings describe patterns observed in these studies where the medicine was studied for differences in symptom duration and stool volume compared to placebo groups.

---

Evidence for use in Acute Diarrhea in Adults

Research into the medicine for adults primarily used short-term RCTs that examined temporary physiological imbalance caused by acute episodes. These studies monitored core outcomes such as the duration of the episode and recovery rates, as well as associated symptoms like physical discomfort from abdominal pain and nausea. Studies describe patterns where measurements of the duration of diarrhea identified variations between the treatment groups and the placebo groups. Further research examined group recovery rates when compared to other symptomatic agents.

---

Evidence Quality and Study Limitations

The evidence quality varies across studies, and for key outcomes in young children, the certainty remains low due to methodological issues. Research highlights that many individual studies carried a moderate to high risk of bias, and inconsistency in reporting certain outcomes contributes to uncertainty in meta-analyses. Consequently, the long-term outcomes are not fully established, and the follow-up durations were limited in existing trials. The current evidence provides insight into short-term changes but offers limited information on long-term symptom patterns.

---

Evidence in Special Populations

Research has explored outcomes in specific populations by age, including infants older than three months and elderly adults. However, evidence for some of the youngest infant populations and individuals with other health conditions is limited. The results apply only to the populations studied, and subgroup findings are uncertain in specific clinical contexts.

---

What Research Gaps and Uncertainties Remain

The evidence overview highlights several areas where the research base is either limited, inconsistent, or still developing, as detailed in the sections above on Evidence Quality and Long-Term Studies.

Key Studies & References Antidiarrheal Medicines Information (NIH/MedlinePlus drug class context)

Common questions about Mold-Aversi (FAQ)

---

Q: Is Mold-Aversi available over the counter?

A: Mold-Aversi is classified as a prescription-only medicine in regulatory guidance. This means the medicine is not available over the counter and requires authorization from a licensed healthcare professional.

---

Q: Does Mold-Aversi cause drowsiness or affect my ability to drive?

A: Official product characteristics describe the medicine as generally having minimal or negligible central nervous system effects. However, in certain cases, some people may experience side effects like dizziness or drowsiness. Official guidance indicates that patients should be aware of how the medicine affects them prior to driving or operating machinery.

---

Q: Is it normal to feel a mild stomach upset when starting Mold-Aversi?

A: Regulatory safety documents classify side effects like nausea and vomiting as uncommon, meaning they affect up to 1 in 100 people. These effects are recognized as components of a mild stomach upset reported when beginning treatment.

---

Q: Can Mold-Aversi be taken with multivitamins?

A: Official drug interaction data indicates that Mold-Aversi does not typically interfere with the major enzymes in the body responsible for processing most medicines and substances. As a result, there are no specific warnings listed against taking the medicine alongside general multivitamins.

---

Q: Are there any long-term effects associated with using Mold-Aversi?

A: Mold-Aversi is strictly intended for short-term use only, and the total course of treatment must not exceed seven days, as defined in regulatory guidelines. Long-term use of the medicine is not recommended due to a lack of sufficient data on outcomes beyond this short duration.

---

Q: What should I do if a side effect of Mold-Aversi seems serious?

A: Regulatory guidance requires caution regarding severe hypersensitivity reactions, such as angioedema (swelling of the face or throat). In the event of a severe skin reaction, the medicine must be discontinued immediately, and official guidance requires close medical supervision until symptoms have completely disappeared.

---

Q: Is it true that Mold-Aversi is a newer type of drug?

A: Mold-Aversi is defined by its selective mechanism as an antisecretory agent that works by modulating fluid and electrolyte transport in the gut. This specific approach is distinct from older, non-selective treatments used for diarrhea that primarily focus on altering intestinal movement.

---

Q: Can I take Mold-Aversi with herbal supplements like St. John's Wort?

A: Official interaction profiles do not list specific data or warnings for combinations with herbal supplements like St. John's Wort. While the medicine generally has a low potential for common drug-drug interactions, any specific herbal combination is a subject for individual consideration.

---

Q: Does alcohol consumption affect how Mold-Aversi works?

A: Regulatory documents indicate that there is no known adverse interaction between the medicine and alcohol when used concomitantly.

---

Q: Can I take Mold-Aversi if I have a heart condition?

A: Official constraints focus primarily on severe impairment of the liver or kidneys, as well as a history of angioedema. No general contraindication is listed for common heart conditions, but any existing health condition, including heart conditions, is a factor that should be considered by a healthcare professional.

---

Q: Are there any reported issues with taking Mold-Aversi with dairy products?

A: The medicine's formulation contains lactose, a sugar component. Regulatory documents state that the medicine is contraindicated for people with rare hereditary problems, such as glucose-galactose malabsorption or lactose intolerance, due to this content.

---

Q: Does Mold-Aversi affect my ability to operate machinery?

A: The official product information states that the medicine generally has minimal impact on a person's ability to drive or use machines. The patient information leaflet indicates that individuals should confirm how the medicine affects them personally.

---

Q: Does taking Mold-Aversi at a specific time of day matter?

A: Yes, regulatory guidelines specify that adult capsules are officially instructed to be taken three times daily. They are preferably taken before the main meals to help maintain a consistent dosing schedule.

---

Q: Is Mold-Aversi safe for people with diabetes?

A: The medicine's formulations contain small amounts of sucrose (a type of sugar) and/or lactose in the excipients. Individuals with diabetes or specific sugar intolerances should take this content into consideration.

---

Q: Can I get Mold-Aversi if I live outside the US?

A: The medicine's regulatory status is covered by official bodies in the US (FDA), Europe (EMA), Canada, Australia, and other global authorities. This indicates that Mold-Aversi is approved and commercially available in many regions internationally.

---

Q: How quickly does Mold-Aversi usually start to work?

A: Official clinical pharmacology data indicates that the inhibition of the target enzyme is typically observed shortly after administration. The onset of the medicine's action is generally reported to be within 1 to 2 hours after being taken orally.

---

Q: What's the difference between Mold-Aversi and older medicines used for similar issues?

A: The medicine is classified as an antisecretory agent. Unlike older drugs, which work by slowing down the movement of the gut, Mold-Aversi functions by reducing excessive fluid and electrolyte secretion without altering intestinal motility.

---

Q: What happens if I forget to take a dose of Mold-Aversi?

A: Regulatory guidance for a missed dose generally advises taking the dose as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose is generally skipped to avoid taking two doses too close together.

---

Q: Is there a generic version of Mold-Aversi available?

A: Yes, as the active ingredient (Racecadotril) is no longer under patent exclusivity in many global jurisdictions, official drug databases confirm that multiple generic versions of the medicine are commercially available.

---

Q: Why might Mold-Aversi not work for some people?

A: Official warnings state the medicine is not recommended for specific conditions. This includes chronic diarrhea, diarrhea associated with antibiotic use, or cases accompanied by fever, bloody stools, or severe vomiting, where the mechanism may be less effective.

---

Q: What kind of medical professional usually prescribes Mold-Aversi?

A: As Mold-Aversi is a prescription-only medicine, it must be prescribed by a healthcare professional who is licensed and authorized to write prescriptions, such as a doctor or specialized practitioner.

---

Q: Is it okay to stop taking Mold-Aversi suddenly?

A: Yes, the treatment is structured as a short-term protocol and is designed to be stopped once the clinical goal is reached (two normal stools). Official instructions do not require a gradual reduction or tapering.

---

Q: Does Mold-Aversi require any special monitoring or blood tests?

A: Official prescribing information indicates that routine clinical monitoring of drug levels in the blood is not typically required for general use. However, general safety precautions apply to patients with existing liver or kidney issues.

---

Q: What are the typical non-serious side effects of Mold-Aversi?

A: The official safety data classifies headache as the most common adverse reaction. Other non-serious effects reported less frequently include general skin reactions like rash, erythema (redness), nausea, and vomiting.

---

Q: What is the purpose of the 'inactive' ingredients in Mold-Aversi?

A: Inactive ingredients, also called excipients, are used to create the final form of the medicine (capsules or granules), ensure product stability, and facilitate proper delivery and absorption of the active substance.

---

Q: Is Mold-Aversi known to cause weight gain or loss?

A: Weight gain or loss is not listed as a common, uncommon, or unknown adverse reaction in the official regulatory safety documents and is not an effect associated with the medicine's mechanism of action.

---

Q: How long does Mold-Aversi stay in the body after the last dose?

A: The active substance is quickly converted in the body, and its active form (Thiorphan) has a relatively short elimination half-life of approximately 3 hours in plasma. The majority of the medicine is typically excreted within 24 hours of the last dose.

---

Q: Do official documents mention any mental or mood changes with Mold-Aversi?

A: Official safety data lists headache as a common nervous system side effect. However, no mental or mood changes, such as psychiatric disorders, are listed as common, uncommon, or unknown frequency adverse reactions.

---

Q: What is the general success rate mentioned in studies of Mold-Aversi?

A: Official product labels do not cite a single 'success rate.' However, clinical trials summarized in regulatory reviews report high rates of clinical success when measuring recovery from acute diarrhea, with reported outcomes varying depending on the study population and the definition of recovery used.

How to Store and Dispose of Mold-Aversi

The storage and disposal of Mold-Aversi (Racecadotril) must strictly follow the conditions defined in the official regulatory labeling to ensure product integrity and safety.

---

Storage Requirements

Mold-Aversi must be stored below 30°C and protected from moisture and light by keeping it in the original packaging (sachets or blisters). This product must always be kept out of the sight and reach of children.

For the granules for oral suspension, any prepared mixture must be used immediately after reconstitution, and any unused portion must be discarded due to stability concerns.

---

Disposal Instructions

Unused or expired Mold-Aversi must not be thrown away via household waste or wastewater. The medicine must be disposed of according to local requirements for pharmaceutical waste, which typically involves returning it to a pharmacy or designated collection point.